Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 370

Sort by

Sort Order Select

Journal Articles

Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies

Blood blood.2024024104.

https://doi.org/10.1182/blood.2024024104

Published: 2024

Includes: Supplemental data

Journal Articles

Phase II Trial of Duvelisib Maintenance after Autologous Stem Cell Transplant in T-Cell and B-Cell Non-Hodgkin Lymphomas: Results of Safety Lead in

Raya Saba, Neha Mehta-Shah, Armin Ghobadi, John F. DiPersio, Amanda F Cashen, Ningying Wu

Blood (2023) 142 (Supplement 1): 6245.

https://doi.org/10.1182/blood-2023-174109

Published: 2023

Journal Articles

Prolonged CXCR4 Receptor Occupancy By Motixafortide Following a Single Subcutaneous Injection Is Associated with Extended Mobilization of CD34+ Cells in Peripheral Blood for > 24 Hours

Zachary David Crees, Keith Stockerl-Goldstein, Ella Sorani, Debby Ickowicz, Liron Darvish, John F. DiPersio

Blood (2023) 142 (Supplement 1): 5777.

https://doi.org/10.1182/blood-2023-184608

Published: 2023

Journal Articles

Use of Combination Premedication Prior to Motixafortide Administration Reduced Severity and Frequency of AEs in the Phase 3 Genesis Trial - a Single Center Analysis

Zachary David Crees, Keith Stockerl-Goldstein, Mark A. Schroeder, Ravi Vij, Ella Sorani, Irit Gliko Kabir, Inbal Goldstein, Tzipi Lustig, Shaul Kadosh, John F. DiPersio

Blood (2023) 142 (Supplement 1): 3522.

https://doi.org/10.1182/blood-2023-181452

Published: 2023

Journal Articles

Itacitinib for the Prevention of Immune Effector Cell Therapy-Associated Cytokine Release Syndrome: Results from the Phase 2 Incb 39110-211 Placebo-Controlled Randomized Cohort

Matthew J. Frigault, Richard T Maziarz, Jae H. Park, Aleksandr Lazaryan, Nirav N. Shah, Jakub Svoboda, Lazaros J. Lekakis, Ran Reshef, Christine L Phillips, Lea M Burke, Jing Lei, Rodica Morariu-Zamfir, John F. DiPersio

Blood (2023) 142 (Supplement 1): 356.

https://doi.org/10.1182/blood-2023-180205

Published: 2023

Journal Articles

Phase 1/2 Dose-Escalation/Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL)

Armin Ghobadi, Ibrahim Aldoss, Shannon L. Maude, Deepa Bhojwani, Alan S. Wayne, Ashish Bajel, Rawan Faramand, Ryan J Mattison, Bhagirathbhai Dholaria, Michael P. Rettig, Ken Jacobs, Ouiam Bakkacha, John Muth, Angela Pannunzio, Brett Ramsey, Eileen McNulty, Matt L. Cooper, Jan Davidson-Moncada, John F. DiPersio

Blood (2023) 142 (Supplement 1): 770.

https://doi.org/10.1182/blood-2023-178723

Published: 2023

Journal Articles

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome with T-Cell Replete Peripheral Blood Haploidentical Transplantation

Ramzi Abboud, Mark A. Schroeder, Michael P. Rettig, Feng Gao, Julie K. Ritchey, Camille N. Abboud, Iskra Pusic, Peter Westervelt, Amanda F Cashen, Matt Christopher, Armin Ghobadi, Ramzi Abboud, Keith Stockerl-Goldstein, Geoffrey L Uy, John F. DiPersio, Leah Gehrs

Blood (2023) 142 (Supplement 1): 651.

https://doi.org/10.1182/blood-2023-180289

Published: 2023

Journal Articles

An “Off-the-Shelf” CD2 Universal CAR-T Therapy Combined with a Long-Acting IL-7 for T-Cell Malignancies

Jingyu Xiang, Jessica Devenport, Alun J Carter, Karl Staser, Michael P. Rettig, Miriam Y Kim, Julie O'Neal, Julie K. Ritchey, Feng Gao, Garrett Rettig, Rolf Turk, Alexandra Wolfarth, Byung Ha Lee, Matthew L. Cooper, John F. DiPersio

Blood (2023) 142 (Supplement 1): 764.

https://doi.org/10.1182/blood-2023-181087

Published: 2023

Journal Articles

Naked Antibody-Based Conditioning Targeting CD47 and CD117 Plus Janus Kinase Inhibition Enables Toxin-Free, Radiation-Free, and Chemotherapy-Free Fully Mismatched Allogeneic Hematopoietic Stem Cell Transplantation

Stephen P. Persaud, Aditya R. Yelamali, Julie K. Ritchey, John F. DiPersio

Blood (2023) 142 (Supplement 1): 3421.

https://doi.org/10.1182/blood-2023-174989

Published: 2023

Journal Articles

Novel Small Molecule VLA-4 Inhibitors Optimized for Extended Hematopoietic and Progenitor Cell Mobilization

Peter Ruminski, Michael P. Rettig, Stephanie Christ, Megh Singh, Ezhilarasi Chendamarai, Leah Gehrs, Julie K. Ritchey, John F. DiPersio

Blood (2023) 142 (Supplement 1): 6778.

https://doi.org/10.1182/blood-2023-181174

Published: 2023

Journal Articles

Targeting Distinct Epitopes of FCRL5 Using CAR-T Generated with Sequences Derived from Newly Identified FCRL5 Humanized Antibodies Resulted in Potent Anti-Myeloma Activity in Vitro and In Vivo

Julie O'Neal, Julie K. Ritchey, Susan Gladney, Gabriel J. Haas, Ramzi Abboud, Michael P. Rettig, Cedric Bruges, Linda Eissenberg, John F. DiPersio

Blood (2023) 142 (Supplement 1): 1922.

https://doi.org/10.1182/blood-2023-183025

Published: 2023

Journal Articles

Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells

Joseph C. Rimando, Ezhilarasi Chendamarai, Michael P. Rettig, Reyka Jayasinghe, Matthew J. Christopher, Julie K. Ritchey, Stephanie Christ, Miriam Y. Kim, Ezio Bonvini, John F. DiPersio

Blood (2023) 141 (14): 1718–1723.

https://doi.org/10.1182/blood.2022017795

Published: 2023

Includes: Supplemental data

Journal Articles

S100A9 upregulated by IFNGR signaling blockade functions as a novel GVHD suppressor without compromising GVL in mice

Sena Kim, Sora Lim, Boram Kim, Julie Ritchey, Kiran Vij, Julie Prior, Lynne Marsala, Alyssa Stoner, Feng Gao, Samuel Achilefu, Matthew L. Cooper, John F. DiPersio, Jaebok Choi

Blood (2023) 141 (8): 945–950.

https://doi.org/10.1182/blood.2021012687

Published: 2023

Includes: Supplemental data

Journal Articles

The role of allogeneic transplant for adult Ph + ALL in CR1 with complete molecular remission: a retrospective analysis

Blood (2022) 140 (20): 2101–2112.

https://doi.org/10.1182/blood.2022016194

Published: 2022

Includes: Supplemental data

Journal Articles

Duvelisib for Critically-Ill Patients with COVID-19 Disease: An Investigator-Initiated, Randomized, Placebo-Controlled Double-Blind Pilot Trial

Scott R. Goldsmith, Fahrettin Covut, Mark A. Fiala, Elizabeth Bradtke, Ayan Gasanli, Brandon Christen, Jonathan A. Pachter, Zhifu Xiang, Zahid Iqbal, Nathan Moore, Uchenna Ofoma, Bijal Parikh, Erik Dubberke, John F. DiPersio

Blood (2022) 140 (Supplement 1): 11185–11186.

https://doi.org/10.1182/blood-2022-157605

Published: 2022

Journal Articles

Modeling Flotetuzumab-Associated CRS in AML Using in Vitro and in Vivo Preclinical Models

Dilan Anil Patel, Ezhilarasi Chendamarai, Julie K. Ritchey, Michael P. Rettig, Leah Gehrs, Paul Moore, Ralph F. Alderson, Ezio Bonvini, Matthew Christopher, John F. DiPersio

Blood (2022) 140 (Supplement 1): 8795–8796.

https://doi.org/10.1182/blood-2022-156943

Published: 2022

Journal Articles

Fully Myeloablative Antibody-Drug Conjugates Condition for Hematopoietic Stem Cell Transplantation and Provide Durable Antileukemia Benefit

Stephen P. Persaud, Aditya R. Yelamali, Julie K. Ritchey, John F. DiPersio

Blood (2022) 140 (Supplement 1): 1570–1571.

https://doi.org/10.1182/blood-2022-157726

Published: 2022

Journal Articles

Streptavidin-Drug Conjugates Streamline Identification of Optimal Toxic Payloads for Antibody-Based Hematopoietic Stem Cell Transplantation Conditioning

Aditya R. Yelamali, Stephen P. Persaud, John F. DiPersio

Blood (2022) 140 (Supplement 1): 7359–7360.

https://doi.org/10.1182/blood-2022-162793

Published: 2022

Journal Articles

A Phase I Safety and Feasibility Study to Evaluate Motixafortide (CXCR4/SDF-1 Inhibition) and Natalizumab (VLA-4/VCAM-1 Inhibition) As a Novel Regimen to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapy in Sickle Cell Disease

Zachary D. Crees, Michael P. Rettig, Reyka G. Jayasinghe, Peter Ruminski, Abi Vainstein, Ella Sorani, Allison A. King, John F. DiPersio

Blood (2022) 140 (Supplement 1): 10432–10433.

https://doi.org/10.1182/blood-2022-165454

Published: 2022

Journal Articles

Outcomes after Transplant in Relapsed/Refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) leukemia Patients Achieving Remissions after Menin Inhibition: SNDX-5613 (revumenib) Ph1 Experience

Blood (2022) 140 (Supplement 1): 914–916.

https://doi.org/10.1182/blood-2022-164600

Published: 2022

NARROW

Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies

Phase II Trial of Duvelisib Maintenance after Autologous Stem Cell Transplant in T-Cell and B-Cell Non-Hodgkin Lymphomas: Results of Safety Lead in

Prolonged CXCR4 Receptor Occupancy By Motixafortide Following a Single Subcutaneous Injection Is Associated with Extended Mobilization of CD34+ Cells in Peripheral Blood for > 24 Hours

Use of Combination Premedication Prior to Motixafortide Administration Reduced Severity and Frequency of AEs in the Phase 3 Genesis Trial - a Single Center Analysis

Itacitinib for the Prevention of Immune Effector Cell Therapy-Associated Cytokine Release Syndrome: Results from the Phase 2 Incb 39110-211 Placebo-Controlled Randomized Cohort

Phase 1/2 Dose-Escalation/Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL)

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome with T-Cell Replete Peripheral Blood Haploidentical Transplantation

An “Off-the-Shelf” CD2 Universal CAR-T Therapy Combined with a Long-Acting IL-7 for T-Cell Malignancies

Naked Antibody-Based Conditioning Targeting CD47 and CD117 Plus Janus Kinase Inhibition Enables Toxin-Free, Radiation-Free, and Chemotherapy-Free Fully Mismatched Allogeneic Hematopoietic Stem Cell Transplantation

Novel Small Molecule VLA-4 Inhibitors Optimized for Extended Hematopoietic and Progenitor Cell Mobilization

Targeting Distinct Epitopes of FCRL5 Using CAR-T Generated with Sequences Derived from Newly Identified FCRL5 Humanized Antibodies Resulted in Potent Anti-Myeloma Activity in Vitro and In Vivo

Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells

S100A9 upregulated by IFNGR signaling blockade functions as a novel GVHD suppressor without compromising GVL in mice

The role of allogeneic transplant for adult Ph + ALL in CR1 with complete molecular remission: a retrospective analysis

Duvelisib for Critically-Ill Patients with COVID-19 Disease: An Investigator-Initiated, Randomized, Placebo-Controlled Double-Blind Pilot Trial

Modeling Flotetuzumab-Associated CRS in AML Using in Vitro and in Vivo Preclinical Models

Fully Myeloablative Antibody-Drug Conjugates Condition for Hematopoietic Stem Cell Transplantation and Provide Durable Antileukemia Benefit

Streptavidin-Drug Conjugates Streamline Identification of Optimal Toxic Payloads for Antibody-Based Hematopoietic Stem Cell Transplantation Conditioning

A Phase I Safety and Feasibility Study to Evaluate Motixafortide (CXCR4/SDF-1 Inhibition) and Natalizumab (VLA-4/VCAM-1 Inhibition) As a Novel Regimen to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapy in Sickle Cell Disease

Outcomes after Transplant in Relapsed/Refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) leukemia Patients Achieving Remissions after Menin Inhibition: SNDX-5613 (revumenib) Ph1 Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only